Pharmacological exploitation of the peroxisome proliferator-activated receptor γ agonist ciglitazone to develop a novel class of androgen receptor-ablative agents

Journal of Medicinal Chemistry

Volumn 51, Issue 7, 2008, Pages 2100-2107

  Yang, Jian ^a   Wei, Shuo ^a   Wang, Da Sheng ^a   Wang, Yu Chieh ^a   Kulp, Samuel K ^a   Chen, Ching Shih ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 HYDROXY 3 TRIFLUOROMETHYLBENZYLIDENE) 3 (1 METHYLCYCLOHEXYLMETHYL)THIAZOLIDINE 2,4; ANDROGEN; ANDROGEN RECEPTOR; CIGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL STRAIN LNCAP; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; ISOMER; MALE; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; PPAR GAMMA; RECEPTORS, ANDROGEN; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINEDIONES;

EID: 41849135388     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701212m     Document Type: Article

References (32)

1. Chen, C. D.; Welsbie, D. S.; Tran, C.; Baek, S. H.; Chen, R.; Vessella, R.; Rosenfeld, M. G.; Sawyers, C. L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10, 33-39.
2. Isaacs, J. T.; Isaacs, W. B. Androgen receptor outwits prostate cancer drugs. Nat. Med. 2004, 10, 26-27.
3. Debes, J. D.; Tindall, D. J. Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med. 2004, 351, 1488-1490.
4. Grossmann, M. E.; Huang, H.; Tindall, D. J. Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl. Cancer Inst. 2001, 93, 1687-1697.
5. Huang, H.; Tindall, D. J. The role of the androgen receptor in prostate cancer. Crit. Rev. Eukaryotic Gene Expression 2002, 12, 193-207.
6. Lee, D. K.; Chang, C. Endocrine mechanisms of disease. Expression and degradation of androgen receptor: mechanism and clinical implication. J. Clin. Endocrinol. Metab. 2003, 88, 4043-4054.
7. Roy-Burman, P.; Tindall, D. J.; Robins, D. M.; Greenberg, N. M.; Hendrix, M. J.; Mohla, S.; Getzenberg, R. H.; Isaacs, J. T.; Pienta, K. J. Androgens and prostate cancer: are the descriptors valid? Cancer Biol. Ther. 2005, 4, 4-5.
8. Taplin, M. E.; Balk, S. P. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J. Cell. Biochem 2004, 91, 483-490.
9. Koivisto, P.; Visakorpi, T.; Kallioniemi, O. P. Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand. J. Clin. Lab. Invest., Suppl. 1996, 226, 57-63.
10. Santos, A. F.; Huang, H.; Tindall, D. J. The androgen receptor: a potential target for therapy of prostate cancer. Steroids 2004, 69, 79-85.
11. Liao, X.; Tang, S.; Thrasher, J. B.; Griebling, T. L.; Li, B. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol. Cancer Ther. 2005, 4, 505-515.
12. Cheng, H.; Snoek, R.; Ghaidi, F.; Cox, M. E.; Rennie, P. S. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res. 2006, 66, 10613-10620.
13. Mitchell, S. H.; Zhu, W.; Young, C. Y. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 1999, 59, 5892-5895.
14. Zhang, Y.; Ni, J.; Messing, E. M.; Chang, E.; Yang, C. R.; Yeh, S. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 7408-7413.
15. Bektic, J.; Berger, A. P.; Pfeil, K.; Dobler, G.; Bartsch, G.; Klocker, H. Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta. Eur. Urol. 2004, 45, 245-251.
16. Yang, C. C.; Ku, C. Y.; Wei, S.; Shiau, C. W.; Chen, C. S.; Pinzone, J. J.; Ringel, M. D.; Chen, C. S. Peroxisome proliferator-activated receptor {gamma}-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells. Mol. Pharmacol. 2006, 69, 1564-1570.
17. Yang, C. C.; Wang, Y. C.; Wei, S.; Lin, L. F.; Chen, C. S.; Lee, C. C.; Lin, C. C.; Chen, C. S. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation. Cancer Res. 2007, 67, 3229-3238.
18. Mustafa, A.; Asker, W.; El-Din Sobhy, M. E. On the reactivity of the exocyclic double bond in 5-arylidene-3-aryl-2,4-thiazolidinediones; their reaction with diazoalkanes, p-thiacresol and piperidine. J. Am. Chem. Soc. 1960, 82, 2597-2601.
19. Jiang, M.; Shappell, S. B.; Hayward, S. W. Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor gamma (PPARgamma) signaling in prostate cancer. J. Cell. Biochem. 2004, 91, 513-527.
20. Koeffler, H. P. Peroxisome proliferator-activated receptor gamma and cancers. Clin. Cancer Res. 2003, 9, 1-9.
21. Lieberman, R. Chemoprevention of prostate cancer: current status and future directions. Cancer Metastasis Rev. 2002, 21, 297-309.
22. Bae, M. A.; Song, B. J. Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol. Pharmacol. 2003, 63, 401-408.
23. Baek, S. J.; Wilson, L. C.; Hsi, L. C.; Eling, T. E. Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J. Biol. Chem. 2003, 278, 5845-5853.
24. Gouni-Berthold, I.; Berthold, H. K.; Weber, A. A.; Ko, Y.; Seul, C.; Vetter, H.; Sachinidis, A. Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway. Naunyn-Schmiedeberg's Arch. Pharmacol. 2001, 363, 215-221.
25. Huang, J. W.; Shiau, C. W.; Yang, Y. T.; Kulp, S. K.; Chen, K. F.; Brueggemeier, R. W.; Shapiro, C. L.; Chen, C. S. Peroxisome proliferator- activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol. Pharmacol. 2005, 67, 1342-1348.
26. Motomura, W.; Okumura, T.; Takahashi, N.; Obara, T.; Kohgo, Y. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res. 2000, 60, 5558-5564.
27. Okura, T.; Nakamura, M.; Takata, Y.; Watanabe, S.; Kitami, Y.; Hiwada, K. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur. J. Pharmacol. 2000, 407, 227-235.
28. Palakurthi, S. S.; Aktas, H.; Grubissich, L. M.; Mortensen, R. M.; Halperin, J. A. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res. 2001, 61, 6213-6218.
29. Shiau, C. W.; Yang, C. C.; Kulp, S. K.; Chen, K. F.; Chen, C. S.; Huang, J. W. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res. 2005, 65, 1561-1569.
30. Sugimura, A.; Kiriyama, Y.; Nochi, H.; Tsuchiya, H.; Tamoto, K.; Sakurada, Y.; Ui, M.; Tokumitsu, Y. Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor. Biochem. Biophys. Res. Commun. 1999, 261, 833-837.
31. Takeda, K.; Ichiki, T.; Tokunou, T.; Iino, N.; Takeshita, A. 15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J. Biol. Chem. 2001, 276, 48950-48955.
32. Wei, S.; Lin, L. F.; Yang, C. C.; Wang, Y. C.; Chang, G. D.; Chen, H.; Chen, C. S. Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor {gamma}. Mol. Pharmacol. 2007, 72, 725-733.